missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Tocris Bioscience™ C25-140
TRAF6-Ubc13 interaction inhibitor
316.00€ - 1230.00€
Specifications
| Chemical Name or Material | 3-[3,5-Dimethyl-1-(3-methyl-1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-1-[4-(phenylmethyl)-1-piperidinyl]-1-propanone |
|---|---|
| CAS | 1358099-18-9 |
| Target | Ubiquitin Ligase (E3) Inhibitors |
| Molecular Formula | C26H31N7O |
| Product Code | Brand | Quantity | Price | Quantity & Availability | |||||
|---|---|---|---|---|---|---|---|---|---|
| Product Code | Brand | Quantity | Price | Quantity & Availability | |||||
|
18766926
|
Tocris Bioscience™
7715/10 |
10 mg |
316.00€
10mg |
Please sign in to purchase this item. Need a web account? Register with us today! | |||||
|
18768896
|
Tocris Bioscience™
7715/50 |
50 mg |
1230.00€
50mg |
Please sign in to purchase this item. Need a web account? Register with us today! | |||||
Description
C25-140 binds directly to TNF receptor-associated factor 6 (TRAF6) and inhibits its interaction with ubiquitin-conjugating enzyme Ubc13. C25-140 reduces TRAF6-Ubc13 activity and decreases NF-κB activation and inflammatory signaling in vitro. C25-140 exhibits selectivity for TRAF6 over other E3 ligases except cIAP1. In in vivo mouse models of autoimmune psoriasis and rheumatoid arthritis, the compound improves disease symptoms. The compound also suppresses the pro-inflammatory signaling activity of IL-17A and prevents its inhibitory effect on the anti-HBV action of IFN-α HepG2 cells.Specifications
| 3-[3,5-Dimethyl-1-(3-methyl-1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-1-[4-(phenylmethyl)-1-piperidinyl]-1-propanone | |
| 1358099-18-9 | |
| Ubiquitin Ligase (E3) Inhibitors | |
| C26H31N7O |
Safety and Handling
Recommended Storage : Store the unopened product at -20 to -70 °C. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Do not use past expiration date.